Flucelvax Quadrivalent is a cell culture-based flu vaccine to help offer protection against 4 flu virus strains that are recommended by the World Health Organization (WHO) the year before the current influenza season.
Flucelvax Quadrivalent is indicated for active immunization of people 4 years of age and older for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine
Flucelvax Quadrivalent is a vaccine for intramuscular injection only.
Flucelvax is the first FDA-approved flu vaccine to use cells, instead of chicken eggs, and represented the first major advance in flu vaccine manufacturing technology since flu vaccine production began in the 1930s.
This modern manufacturing process allows the flu shot to be antibiotic free, helps protect against the identified 4 flu strains for 2019-2020, and is well tolerated.
Flucelvax Quadrivalent is also preservative and latex free.